Related Experiment Video
Updated: Jun 17, 2026
Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
The effect of etoricoxib, a cyclooxygenase-2-specific inhibitor, on the 1,2-dimethylhydrazine-administered rat
Neha Mittal1, Shailender Singh Kanwar, Sankar Nath Sanyal
1Department of Biophysics, Panjab University, Chandigarh, India.
Abstract:
ABSTRACT To gain insight into the chemopreventive effects of etoricoxib, which is a selective inhibitor of cycloxygenase-2, a study was carried out in the procarcinogen 1,2-dimethylhydrazine-treated rat intestine. The male Sprague Dawley rats were divided into three different groups. Group 1 served as control (vehicle treated). All animals in Group 2 were given a weekly subcutaneous injection of 1,2-dimethylhydrazine (DMH; 30 mg/kg body weight) for 6 weeks. Group 3 animals were given an additional oral dose of etoricoxib (6 mg/kg body weight) along with weekly DMH injections for 6 weeks. At the end of 6 weeks of treatments, the results indicated significant alterations in the biochemical parameters, membrane lipid composition, and membrane fluorescence studies of the intestine in the presence of DMH, which were recovered nearly to the control level and, therefore, may suggest the chemopreventive efficacy of etoricoxib against the experimental intestinal cancer in rats.
Insights
Etoricoxib, a selective cyclooxygenase-2 inhibitor, shows chemopreventive potential against experimental intestinal cancer. It helped restore biochemical and membrane alterations induced by 1,2-dimethylhydrazine in rats.
Area of Science:
- Oncology
- Pharmacology
- Gastroenterology
Background:
- 1,2-dimethylhydrazine (DMH) is a procarcinogen used to induce experimental intestinal cancer in animal models.
- Cyclooxygenase-2 (COX-2) is implicated in colorectal cancer development and progression.
- Etoricoxib is a selective COX-2 inhibitor with potential anti-inflammatory and anti-cancer properties.
Purpose of the Study:
- To investigate the chemopreventive efficacy of etoricoxib against DMH-induced intestinal cancer in rats.
- To evaluate the effects of etoricoxib on biochemical parameters and membrane properties in the rat intestine during chemical carcinogenesis.
Main Methods:
- Male Sprague Dawley rats were divided into three groups: control, DMH-treated, and DMH plus etoricoxib-treated.
- Groups received weekly subcutaneous injections of DMH (30 mg/kg) for 6 weeks.
- The third group also received an oral dose of etoricoxib (6 mg/kg) concurrently with DMH treatment.
Main Results:
- DMH treatment caused significant alterations in intestinal biochemical parameters, membrane lipid composition, and membrane fluorescence.
- Co-administration of etoricoxib with DMH largely restored these altered parameters to levels comparable to the control group.
- These findings suggest a protective effect of etoricoxib against DMH-induced intestinal damage.
Conclusions:
- Etoricoxib demonstrates significant chemopreventive efficacy in an experimental model of intestinal cancer.
- The study suggests that targeting COX-2 with etoricoxib may be a viable strategy for preventing or treating intestinal cancer.
- Further research is warranted to explore the detailed mechanisms underlying etoricoxib's chemopreventive effects.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...